CHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common stock at a price to the public of $6.00 per share. Cempra also has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares to cover over-allotments, if any.
Shares of Cempra’s common stock will trade on the NASDAQ Global Market under the symbol “CEMP” beginning on February 3, 2012. The closing of the offering is expected to occur on February 8, 2012, subject to the satisfaction of customary closing conditions.
Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.
The offering of these securities will be made only by means of a prospectus. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A copy of the prospectus relating to the offering may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Leerink Swann LLC, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling (800) 808-7525; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling (631) 274-2806. The final prospectus, when it is available, also may be obtained on the Securities and Exchange Commission’s Web site at www.sec.gov.
About Cempra
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.
Contact:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com
Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com
Dr. Prabhavathi Fernandes
President and Chief Executive Officer
(919) 467-1716
pfernandes@cempra.com
SOURCE Cempra, Inc.
